Dr. Reddy's Laboratories (RDY) said Thursday it has a licensing agreement with Shanghai Henlius Biotech for HLX15, an investigational daratumumab biosimilar to treat multiple myeloma.
The agreement grants Dr. Reddy's exclusive commercialization rights for both subcutaneous and intravenous formulations of HLX15 in the US and Europe, the company said.
Henlius will manage development, manufacturing and supply, potentially earning up to $131.6 million, including a $33 million upfront payment, milestone payments, and royalties on net annual sales of the product.
HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and is being developed as a biosimilar of Darzalex and Darzalex Faspro, manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson.
Dr. Reddy shares rose 0.1% in recent Thursday trading, and Johnson & Johnson fell 0.5%.
Price: 13.99, Change: +0.01, Percent Change: +0.11
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。